Lilly maintains focus on its pharmaceuticals: Drugmaker has no plans to replicate J&J’s diversity
Johnson & Johnson loves to profit from a balanced product line, and it has competitor Eli Lilly and Co. to thank-in a roundabout way-for its latest bit of leverage. New Jersey-based J&J plans to expand its medical device business by buying Guidant Corp., which Lilly created and then spun off in the early 1990s. J&J leaders think the proposed, $25.4 billion deal will create better balance among a line of businesses that has been led by pharmaceuticals, which made up…